Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 beta. Methods of using these compounds for modulation of glycogen synthase kinase 3 beta expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 beta are provided.
Claims What is claimed is: 1. An antisense compound 8 to 30 nucleobases in length targeted to nucleotides 21 through 46 or nucleotides 57 through 70 of a 5' untranslated region of human glycogen synthase kinase 3 beta (SEQ ID NO:10), nucleotides 60 through 142, nucleotides 154 through 173, nucleotides 224 through 269, nucleotides 294 through 313, nucleotides 326 through 385, nucleotides 396 through 423, nucleotides 428 through 470, nucleotides 509 through 528, nucleotides 535 through 583, nucleotides 592 through 658, nucleotides 676 through 725, nucleotides 745 through 767, nucleotides 783 through 812, nucleotides 820 through 839, nucleotides 874 through 899, nucleotides 963 through 982, nucleotides 1002 through 1145, nucleotides 1155 through 1203, nucleotides 1244 through 1291 of a coding region, nucleotides 1292 through 1311 of a stop codon, or nucleotides 1327 through 1383 of a 3' untranslated region of human glycogen synthase kinase 3 beta (SEQ ID NO:3), wherein said antisense compound specifically hybridizes with and inhibits the expression of human glycogen synthase kinase 3 beta. 2. The antisense compound of claim 1 which is an antisense oligonucleotide. 3. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 4. The antisense compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage. 5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 6. The antisense compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 8. The antisense compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine. 9. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 10. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 11. The composition of claim 10 further comprising a colloidal dispersion system. 12. The composition of claim 10 wherein the antisense compound is an antisense oligonucleotide. 13. A method of inhibiting the expression of glycogen synthase kinase 3 beta in human cells or tissues comprising contacting said human cells or tissues in vitro with the antisense compound of claim 1 so that the expression of human glycogen synthase kinase 3 beta is inhibited. 14. An antisense compound up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 11, 12, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 58, 60, 61, 62, 63, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 78, 79, 80, 81, 82, 83, 84 or 85 which inhibits the expression of human glycogen synthase kinase 3 beta. 15. The antisense compound of claim 14 which is an antisense oligonucleotide. 16. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 17. The antisense compound of claim 16 wherein the modified internucleoside linkage is a phosphorothioate linkage. 18. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 19. The antisense compound of claim 18 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 20. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 21. The antisense compound of claim 20 wherein the modified nucleobase is a 5-methylcytosine. 22. The antisense compound of claim 15 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 23. A composition comprising the antisense compound of claim 14 and a pharmaceutically acceptable carrier or diluent. 24. The composition of claim 23 further comprising a colloidal dispersion system. 25. The composition of claim 23 wherein the antisense compound is an antisense oligonucleotide. 26. A method of inhibiting the expression of human glycogen synthase kinase 3 beta in human cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 14 so that expression of human glycogen synthase kinase 3 beta is inhibited. 